In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type

Type

Guidance programme 1 selected

Guidance programme

Showing 251 to 287 of 287

TitleTypeExpected publication date
Targeted-release budesonide for treating primary IgA nephropathy (review of TA937) [ID6485]Technology appraisal guidance
Tarlatamab for previously treated advanced small-cell lung cancer [ID6364]Technology appraisal guidance
Taselisib for previously treated ER-positive, HER2-negative, PIK3CA-positive breast cancer in postmenopausal women ID1401Technology appraisal guidanceTBC
Telisotuzumab vedotin for treating c-MET overexpressed, EGFR wild-type, non-squamous advanced non-small-cell lung cancer after 1 or more systemic treatments [ID6253]Technology appraisal guidanceTBC
Teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes [ID6259]Technology appraisal guidance
Teprotumumab for treating thyroid eye disease [ID6432]Technology appraisal guidance
Third molars (impacted) - prophylactic removal [ID898]Technology appraisal guidanceTBC
Tislelizumab for treating advanced non-small-cell lung cancer after platinum-based chemotherapy ID6161Technology appraisal guidanceTBC
Tislelizumab with chemotherapy for untreated advanced oesophageal squamous cell cancer ID5113Technology appraisal guidanceTBC
Tisotumab vedotin for treating recurrent or metastatic cervical cancer after chemotherapy ID3753Technology appraisal guidanceTBC
Tolebrutinib for treating secondary progressive multiple sclerosis ID6351Technology appraisal guidanceTBC
Topical rapamycin for treating facial angiofibromas associated with tuberous sclerosis complex in people 6 years and over [ID6391]Technology appraisal guidanceTBC
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments [ID6309]Technology appraisal guidanceTBC
Treatments for non-small-cell lung cancer [ID6234]Technology appraisal guidanceTBC
Triheptanoin for treating long-chain fatty acid oxidation disorders [ID3891]Technology appraisal guidanceTBC
Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together [ID6165]Technology appraisal guidanceTBC
Tucatinib with trastuzumab for previously treated HER2-positive colorectal cancer [ID6227]Technology appraisal guidanceTBC
Upadacitinib for treating giant cell arteritis [ID6299]Technology appraisal guidance
Vanzacaftor–tezacaftor–deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people aged 6 years and over [ID6372]Technology appraisal guidance
Veliparib with carboplatin and paclitaxel for untreated non-squamous non-small-cell lung cancer [ID1277]Technology appraisal guidanceTBC
Venetoclax with azacitidine for untreated high-risk myelodysplastic syndromes [ID6314]Technology appraisal guidanceTBC
Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia when there is no 17p deletion or TP53 mutation and FCR (fludarabine, cyclophosphamide, rituximab) or BR (bendamustine, rituximab) are suitable (MA partial review of TA663) [ID6291]Technology appraisal guidance
Venglustat for treating gangliosidoses in people 2 years and over ID 6358Technology appraisal guidanceTBC
Vepdegestrant for treating hormone receptor-positive HER2-negative metastatic breast cancer after endocrine treatment [ID6360]Technology appraisal guidanceTBC
Vibostolimab–pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID6382]Technology appraisal guidanceTBC
Vimseltinib for treating tenosynovial giant cell tumours when surgery is unsuitable TSID 12099Technology appraisal guidanceTBC
Vocimagene amiretrorepvec with extended-release 5-fluorocytosine for treating recurrent high-grade glioma [ID1425]Technology appraisal guidanceTBC
Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over [ID6407]Technology appraisal guidance
Vosoritide for treating achondroplasia in people 4 months and over ID6488Technology appraisal guidanceTBC
Vutrisiran for treating transthyretin-related amyloidosis cardiomyopathy [ID6470]Technology appraisal guidance
Waldenstrom's macroglobulinaemia - ibrutinib [ID884]Technology appraisal guidance
Xevinapant with platinum-based chemotherapy and radiotherapy for untreated locally advanced squamous cell head and neck cancer [ID6199]Technology appraisal guidanceTBC
Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more systemic treatments [ID6388]Technology appraisal guidance
Zanubrutinib for treating relapsed or refractory mantle cell lymphoma after 1 or more treatments [ID6392]Technology appraisal guidanceTBC
Zanubrutinib for untreated chronic lymphocytic leukaemia [ID5079]Technology appraisal guidanceTBC
Zilucoplan for treating antibody positive generalised myasthenia gravis [ID4008]Technology appraisal guidanceTBC
Zuranolone for treating postnatal depression [ID6431]Technology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All